What Happens When an Aging Liver Gets Its Filters Back?

Key takeaways

• In older rats, two weeks of an experimental drug restored features of specialized liver cells that help substances move out of the bloodstream.

• Circulating amyloid-beta fell by approximately 50%, while LDL cholesterol returned to levels comparable to those in younger animals.

• The treatment also restored communication between neighboring liver cells, helping explain why its effects extended beyond the physical filtering system.

• These are animal findings. Lowering amyloid-beta in blood does not establish that deposits in the brain decrease or that memory improves.

The liver’s problem may start at the entrance

The liver can only process what reaches its working cells.

Inside its tiny blood vessels, specialized lining cells contain microscopic openings that allow substances in the blood to reach neighboring hepatocytes—the cells responsible for much of the liver’s processing and clearance work.

With age, those openings shrink or disappear. The machinery on the other side may still be present, but access becomes more difficult.

Researchers at the University of Southern California investigated whether restoring these gateway cells could improve the aging liver’s ability to clear the blood.

Two weeks, two notable changes

The team treated older rats with cinaciguat, an experimental drug, for two weeks. They compared the results with untreated older and younger animals.

Treatment restored the microscopic openings and improved the function of the blood-vessel lining cells, known as liver sinusoidal endothelial cells.

Circulating amyloid-beta—a protein that can accumulate in the brain—fell by approximately half, reaching levels comparable to those in young rats.

Then came an unexpected result: LDL cholesterol also dropped to youthful levels.

The researchers had included LDL as a comparison measure, not something they expected to respond. Its decline suggested that reopening the filters was not the whole explanation.

A conversation between cells

Further experiments revealed a second mechanism: communication.

Cinaciguat activated an enzyme called soluble guanylate cyclase in the vessel-lining cells. Those cells then released HB-EGF, a growth factor that signaled to neighboring hepatocytes.

In response, the hepatocytes changed their surfaces in ways that helped them capture more LDL and amyloid-beta.

Aging had weakened this exchange. The drug restored it.

That makes the finding more interesting than a simple “cleaner filter” story. The treatment appeared to improve both access to the liver’s working cells and the instructions those cells received.

Why a liver finding raises brain-health questions

The liver helps remove circulating amyloid-beta. That creates a plausible connection between clearance outside the brain and the handling of a protein relevant to brain aging.

It also offers a potential research advantage: a treatment directed at the liver would not necessarily need to cross the blood–brain barrier.

But the crucial link remains unproven.

A lower blood concentration does not automatically mean fewer brain deposits, better cognition, or lasting protection. This study did not demonstrate those outcomes. Researchers plan further animal experiments to determine whether the clearance changes translate into meaningful benefits.

Reversing a feature is not reversing aging

The treatment restored important structural and functional features of one specialized cell population.

That is not equivalent to making the entire liver young again, reversing whole-body aging, or extending lifespan.

The findings also do not establish a human dose, long-term safety, or a reason to use cinaciguat outside research. No food, supplement, or “liver detox” routine was tested.

The takeaway

Restoring aging liver cells improved more than their microscopic openings: it revived a signaling partnership that helped clear substances from the blood.

The next challenge is to determine whether that improvement produces lasting benefits elsewhere in the body—and whether it can be achieved safely in people.

References:

1. Sam J. de Leve, Xiangdong Wang, Helia Alavifard, Lily Dara, Laurie D. DeLeve. Reversing liver sinusoidal endothelial aging restores clearance of amyloid-beta and LDL. Journal of Biological Chemistry, 2026; 302 (11): 113608 DOI: 10.1016/j.jbc.2026.113608